Drug Search Results
More Filters [+]

Amprenavir

Alternative Names: amprenavir, agenerase
Latest Update: 2023-12-01
Latest Update Note: Clinical Trial Update

Product Description

Amprenavir is a Protease Inhibitor. The mechanism of action of amprenavir is as a HIV Protease Inhibitor, and Cytochrome P450 3A4 Inhibitor, and Cytochrome P450 3A4 Inducer, and P-Glycoprotein Inducer. Amprenavir is a tetrahydrofuryl ester, a sulfonamide and a carbamate ester. It has a role as a HIV protease inhibitor and an antiviral drug. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Amprenavir)

Mechanisms of Action: HIV Protease Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Canada | Chile | Colombia | European Medicines Agency | Germany | Hungary | Ireland | Italy | New Zealand | Portugal | Russia | Slovenia | Sweden | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Amprenavir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events